Yong Yu - Genelux Common Senior Development
| GNLX Stock | 2.56 0.01 0.39% |
Executive
Yong Yu is Senior Development of Genelux Common
| Age | 53 |
| Address | 2625 Townsgate Road, Westlake Village, CA, United States, 91361 |
| Phone | 805 267 9889 |
| Web | https://www.genelux.com |
Yong Yu Latest Insider Activity
Tracking and analyzing the buying and selling activities of Yong Yu against Genelux Common stock is an integral part of due diligence when investing in Genelux Common. Yong Yu insider activity provides valuable insight into whether Genelux Common is net buyers or sellers over its current business cycle. Note, Genelux Common insiders must abide by specific rules, including filing SEC forms every time they buy or sell Genelux Common'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Yong Yu over a month ago Disposition of 5200 shares by Yong Yu of Genelux Common at 19.106 subject to Rule 16b-3 | ||
Yong Yu over three months ago Disposition of 18665 shares by Yong Yu of Genelux Common at 10.2628 subject to Rule 16b-3 | ||
Yong Yu over three months ago Acquisition by Yong Yu of 2500 shares of Genelux Common at 4.0 subject to Rule 16b-3 |
Genelux Common Management Efficiency
The company has return on total asset (ROA) of (0.4461) % which means that it has lost $0.4461 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8857) %, meaning that it created substantial loss on money invested by shareholders. Genelux Common's management efficiency ratios could be used to measure how well Genelux Common manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.07 in 2024. Return On Capital Employed is likely to rise to -1.08 in 2024. At this time, Genelux Common's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 25.4 M in 2024, whereas Net Tangible Assets are likely to drop (31.3 M) in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Emil MD | Terns Pharmaceuticals | 44 | |
| Nicolas Mosimann | MoonLake Immunotherapeutics | N/A | |
| Tammy Sarnelli | Amylyx Pharmaceuticals | N/A | |
| Douglas Kling | NewAmsterdam Pharma | 51 | |
| Rebecca Cohen | Ikena Oncology | N/A | |
| Luciana Marques | MoonLake Immunotherapeutics | N/A | |
| Adam JD | Day One Biopharmaceuticals | 57 | |
| Sheng Cui | NewAmsterdam Pharma | N/A | |
| Thomas Dalton | Cingulate | N/A | |
| JD Esq | Terns Pharmaceuticals | 55 | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Nathalie Harroy | Inventiva Sa | 57 | |
| Jim Jacobson | NewAmsterdam Pharma | N/A | |
| Jennifer Callahan | Cingulate | 53 | |
| Harris Rotman | Centessa Pharmaceuticals PLC | N/A | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| Gina JD | Amylyx Pharmaceuticals | 53 | |
| Edmund Dunn | Monte Rosa Therapeutics | 58 | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| Kristina Meyer | Inventiva Sa | N/A | |
| Jennifer Johansson | Larimar Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.89 | ||||
| Return On Asset | -0.45 |
Genelux Common Leadership Team
Elected by the shareholders, the Genelux Common's board of directors comprises two types of representatives: Genelux Common inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genelux. The board's role is to monitor Genelux Common's management team and ensure that shareholders' interests are well served. Genelux Common's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genelux Common's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ralph BSc, Head Affairs | ||
| Sean JD, General Secretary | ||
| Lourie Zak, Chief Officer | ||
| Joseph Cappello, Chief Officer | ||
| Thomas JD, CEO Chairman | ||
| Caroline Jewett, VP Quality | ||
| Yong Yu, Senior Development | ||
| Pr MD, Chief Officer |
Genelux Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genelux Common a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.89 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 56.4 M | ||||
| Shares Outstanding | 34.54 M | ||||
| Shares Owned By Insiders | 16.28 % | ||||
| Shares Owned By Institutions | 15.70 % | ||||
| Number Of Shares Shorted | 1.43 M | ||||
| Price To Book | 2.67 X | ||||
| Price To Sales | 11,052 X | ||||
| Revenue | 170 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Genelux Stock Analysis
When running Genelux Common's price analysis, check to measure Genelux Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genelux Common is operating at the current time. Most of Genelux Common's value examination focuses on studying past and present price action to predict the probability of Genelux Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genelux Common's price. Additionally, you may evaluate how the addition of Genelux Common to your portfolios can decrease your overall portfolio volatility.